FDA studies possible pre-cancerous link with diabetes drugs

Your Health Matters

A view shows the U.S. Food and Drug Administration (FDA) headquarters in Silver SpringBy Ransdell Pierson (Reuters) – The U.S. Food and Drug Administration is studying unconfirmed reports that a widely used class of diabetes drugs, which includes Merck & Co's Januvia, may cause inflammation of the pancreas and pre-cancerous changes to the pancreas. The agency, in a notice on its website on Thursday, said it is the first time it has communicated potential pre-cancerous links to the medicines, known as incretin mimetics. The oral treatments also include Onglyza from Bristol-Myers Squibb Co and AstraZeneca PLC. …

facebookShare on Facebook
TwitterTweet
FollowFollow us
PinterestSave